SPARC-1: A Phase I Trial of Neoadjuvant IL-1beta and PD-1 Blockade in Localized Renal Cell Carcinoma

Background:Immune checkpoint blockade has significantly improved outcomes for patients with renal cell carcinoma (RCC) in the metastatic setting. However, there is currently no neoadjuvant systemic therapy that improves outcomes for patients with loc...